Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

160
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
160
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

263
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
263
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

195
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
195
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

143
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
143
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

2.1K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Knowledge and perspectives on pharmacogenomic-guided antidepressant treatment among psychiatrists and primary care practitioners.

Pharmacogenetics and genomics·2026
Same author

Effect of Individual and Combined Cytochrome P450 Activity Scores on Symptom Improvement and Side Effects in Youth Treated With Sertraline.

Clinical and translational science·2026
Same author

Structured Online Support to Inform and Assist Antidepressant Deprescribing in Primary Care: Protocol for a Pragmatic, Randomized Controlled Trial (The WiserAD Trial).

JMIR research protocols·2026
Same author

Characteristics of initial pharmacogenetic testing and subsequent physician referral behavior in youth mental health.

Pharmacogenetics and genomics·2026
Same author

PharmVar GeneFocus: CYP1A2-Clinical Impact, Genetic Variation, and Updated Nomenclature.

Clinical pharmacology and therapeutics·2026
Same author

Polygenic scores and physical fitness prediction: a systematic review.

Human genetics·2026
Same journal

Neuroimaging in older-age bipolar disorder.

Current opinion in psychiatry·2026
Same journal

Repetitive transcranial magnetic stimulation treatment for obsessive-compulsive disorder.

Current opinion in psychiatry·2026
Same journal

Pharmacological maintenance treatment in older age bipolar disorder.

Current opinion in psychiatry·2026
Same journal

Harmful behaviours and suicide in later life bipolar disorder.

Current opinion in psychiatry·2026
Same journal

Urbanization, wildfire exposure, and youth mental health: a narrative review.

Current opinion in psychiatry·2026
Same journal

Bipolar disorder and the risk of developing dementia - a systematic review and meta-analysis.

Current opinion in psychiatry·2026
See all related articles

Related Experiment Video

Updated: May 5, 2026

The Forced Swim Test as a Model of Depressive-like Behavior
05:42

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

39.0K

Antidepressant pharmacogenetics.

Ajeet B Singh1, Chad A Bousman, Chee Ng

  • 1aIMPACT Strategic Research Centre, School of Medicine, Deakin University, Geelong bDepartment of Psychiatry cDepartment of General Practice, The University of Melbourne dFlorey Institute for Neuroscience and Mental Health, Parkville eCentre for Human Psychopharmacology, Swinburne University of Technology, Hawthorn fOrygen Youth Health Research Centre, Parkville, Australia.

Current Opinion in Psychiatry
|November 26, 2013
PubMed
Summary
This summary is machine-generated.

Antidepressant pharmacogenetics shows promise but requires more robust evidence. Current genetic tests for major depressive disorder (MDD) are not yet ready for routine clinical use due to mixed findings and methodological challenges.

More Related Videos

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

747
The Mouse Forced Swim Test
06:19

The Mouse Forced Swim Test

Published on: January 29, 2012

107.1K

Related Experiment Videos

Last Updated: May 5, 2026

The Forced Swim Test as a Model of Depressive-like Behavior
05:42

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

39.0K
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

747
The Mouse Forced Swim Test
06:19

The Mouse Forced Swim Test

Published on: January 29, 2012

107.1K

Area of Science:

  • Pharmacogenetics
  • Neuroscience
  • Clinical Pharmacology

Background:

  • The field of antidepressant pharmacogenetics has advanced significantly.
  • Numerous genetic polymorphisms have been linked to variations in antidepressant response.

Purpose of the Study:

  • To review recent literature on antidepressant pharmacogenetics.
  • To focus on clinical translation and methodological challenges.
  • To assess the current evidence base for clinical utility.

Main Methods:

  • Literature review of studies published between March 2012 and August 2013.
  • Analysis of association studies investigating genetic polymorphisms and antidepressant outcomes.
  • Evaluation of methodological challenges and confounders in existing research.

Main Results:

  • While polymorphisms associated with antidepressant efficacy and tolerability have been identified, findings are often mixed.
  • Limited effect sizes and inadequate control for confounders hinder clinical translation.
  • Empirically robust, clinically translatable pharmacogenetic tests are not yet established.
  • The complex neurobiology of major depressive disorder (MDD) presents research challenges.

Conclusions:

  • Early reports suggest potential clinical utility for antidepressant pharmacogenetics.
  • The current evidence is insufficient to guide routine prescribing.
  • Future genetically guided versus unguided trials are necessary to determine widespread application.